Anionic Lipid Hemostatic Material for Low Platelet Counts
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing hemostatic materials rely on substances like collagen and gelatin that require sufficient platelet counts or functions, limiting their effectiveness in patients with low platelet counts or dysfunction.
Innovation Solution
A hemostatic material comprising a water-insoluble base with anionic lipids supported on its surface, which accelerates platelet adhesion and aggregation without relying on proteins like GPIb or H12, enhancing hemostasis in conditions where conventional materials are ineffective.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional hemostatic materials (collagen, gelatin) are used, then hemostasis can be achieved in patients with normal platelet function, but they are ineffective in patients with low platelet counts or platelet dysfunction
Solution Approach 1:
The invention changes the chemical parameter of the lipid material by introducing anionic lipids with specific charge characteristics. This parameter change enables the material to interact with platelets through electrostatic interactions, allowing it to function effectively even when platelet counts are low or platelet function is impaired, thus resolving the contradiction between hemostatic effectiveness and adaptability to pathological conditions
Solution Approach 2:
The invention creates a composite hemostatic material combining a base substrate with anionic lipid components. This composite structure integrates the mechanical properties of the base material with the platelet-interacting properties of anionic lipids, achieving both reliable hemostasis and adaptability to patients with platelet disorders
2Reliability
If lipid particles carrying platelet membrane proteins (GPIb, H12) are used as platelet substitutes, then platelet adhesion and aggregation are enhanced, but the system becomes more complex and requires specific protein components
Solution Approach 1:
The invention extracts the essential functional property (anionic charge) from complex platelet membrane proteins and implements it through simpler anionic lipid molecules. This extraction eliminates the need for complex protein components while retaining the platelet adhesion and aggregation acceleration effects, thus resolving the contradiction between reliability and device complexity
Solution Approach 2:
The invention simplifies the system by changing the compositional parameter from protein-based to lipid-based anionic components. This parameter change maintains the essential electrostatic interaction capability with platelets while dramatically reducing system complexity, as anionic lipids are simpler molecules that do not require the complex structural and functional properties of membrane proteins
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The material effectively promotes rapid and stable clot formation by supporting platelet adhesion and aggregation, even in patients with low platelet counts or dysfunction, providing a potent hemostatic effect.
Implementation Method 1
the lipid comprises one or two or more anionic lipids
Data Source
AI summary
A hemostatic material includes a lipid that can accelerate adhesion or aggregation of platelets even if the lipid does not carry a protein or a peptide involved in adhesion or aggregation of platelets such as GPIb and H12 and, to achieve the object, provides a hemostatic material including a water-insoluble base and a lipid supported on a surface of the base, wherein the lipid includes one or two or more anionic lipids.